Font Size: a A A

Cpv - 2, Cpv - 2 A Immune Cross Protection Research And Cpv Resistance - 2 A Rabbit Polyclonal Antibody Preparation

Posted on:2013-08-05Degree:MasterType:Thesis
Country:ChinaCandidate:S Q LiFull Text:PDF
GTID:2243330395978709Subject:Clinical Veterinary Medicine
Abstract/Summary:PDF Full Text Request
To study the antigenic relationship among the original canine parvovirus type2and the variants CPV-2a, which is the main canine parvovirus type in China, in the situation of clinical vaccine is CPV-2and the serum used to treatment is primed by CPV-2vaccine. Research was carried out by serologic test, to analyze whether homologous protection is higher than the other. CPV-2a polyclone antibody and CPV-2polyclone antibody were prepared to compare the therapeutic efficacy.the advantage strain (CPV-YA-ZA1) and CPV-2vaccine were picked out to be obtained and generally amplified in the F81cells. The amplified strain was condensed with PEG6000and diluted in appropriate titration with PBS. The viral suspension was emulsified with the adjuvant to immune six rabbits which were CPV negative by PCR and HI. And clinical vaccine (CPV-2) was used to immune five CPV negative Dogs. Their serum samples were collected during immunity. Then the antibody titer was separated tested with CPV-2&CPV-2a strains by SN and HI and data was analyzed by SPSS. All the rabbits were euthanatized to get the serum after immunizing four times when antibody titer wasn’t raised up any more. Two anti-CPV IgG was concentrated and purified with saturated ammonium sulfate. After analyzing the IgG with HI and Protein concentration, testing aseptic and safety, were separated treated2dogs which was inoculation CPV-2a and infected. Blood samples were collected every day during treatment. Then they were analyzed by SPSS. Furthermore, clinical investigation was taken in order to get the enlarged statistical data.The results showed that the advantage antigen virulence was higher than the others. CPE in F81cell was obvious when CPV-YA-ZA1wan inoculated and induced the higher antibody titer which average titer was HI>1:10240, SN≥1:51200. Antigenic differences were found between CPV-2,CPV-2a. Dogs immunized with CPV-2had higher HI&SN titers to CPV-2, there was a significant difference (P<0.05). Rabbits immunized with CPV-2a was more significant to CPV-2a than the other one, HI&SN titers was higher (3413,6826) than CPV-2primed antibody (421,341).The CPV-2a polyclonal antibody was given more protection against CPV-2a which was epidemic in Sichuan province by HI and SN (P<0.05). Homologous protection was better. WBC of dogs treated with Anti CPV-2a polyclone antibody was faster recovery to normal level than the other in experimental therapeutic, CPV-2polyclone antibody group mostly recovered to normal in4-5d. The treatment had significant difference (P<0.05). Results of Anti CPV-2a polyclone antibody in clinical treatment were satisfactory. Protection rate was91.6%.
Keywords/Search Tags:CPV-2, CPV-2a, Antibody, Cross-Antigenic protection, Polyclone antibody
PDF Full Text Request
Related items